Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGB101 in ApoE4 Non-carriers with MCI due to AD
NCT05986721Phase 2Withdrawn
- Sponsor
- AgeneBio
- Start
- Dec 2024
- Primary completion
- Jul 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mild cognitive impairment due to Alzheimer's disease comparing AGB101 with Placebo (2 arms). Primary endpoint: Change in Entorhinal Cortex Volume at 78 weeks. Planned start Dec 2024; status: withdrawn.
02
Drugs
levetiracetam
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NCT05986721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986721.